
|Articles|January 10, 2005
RA after Vioxx: What Now?
Treating rheumatoid arthritis is challenging enough as it is without the latest studies linking COX-2 inhibitors, often used as adjunct therapy, with an increased heart risk. These studies have left many RA patients and physicians a bit apprehensive about continuous high-dose therapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Dementia Increases Risk of COVID-19 Infection, Hospitalization for Older Patients
2
Pharmacists Provide Tailored Pneumococcal Vaccines to Patients With Down Syndrome
3
FDA Approves Lumateperone as Adjunct Therapy for Major Depressive Disorder
4
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
5




















































































































































